{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T19:21:30Z","timestamp":1788376890583,"version":"build-2803163510"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:00:00Z","timestamp":1761868800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:00:00Z","timestamp":1761868800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Sciences Foundation of China","doi-asserted-by":"crossref","award":["82170974"],"award-info":[{"award-number":["82170974"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Central South University Research Program of Advanced Interdisciplinary Studies","award":["2023QYJC038"],"award-info":[{"award-number":["2023QYJC038"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Syst Rev"],"DOI":"10.1186\/s13643-025-02958-1","type":"journal-article","created":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T08:22:16Z","timestamp":1761898936000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Comparative efficacy and safety of cabazitaxel versus other taxanes: a systematic review and meta-analysis"],"prefix":"10.1186","volume":"14","author":[{"given":"Salah Ameen","family":"Abdu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"He","family":"Caiyun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wafa Ali","family":"Asaad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad","family":"Tufail","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liao","family":"Yazhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sadam Ahmed","family":"Elayah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rao","family":"Zhen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siying","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad H.","family":"Shubair","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ning","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,31]]},"reference":[{"key":"2958_CR1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.789319","volume":"12","author":"J Chen","year":"2021","unstructured":"Chen J, Zhang Y, Zhang X, Zhao J, Ni Y, Zhu S, et al. Comparison of systemic treatments for metastatic castration-resistant prostate cancer after docetaxel failure: a systematic review and network meta-analysis. Front Pharmacol. 2021;12:789319.","journal-title":"Front Pharmacol"},{"issue":"3","key":"2958_CR2","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1177\/1756287214528557","volume":"6","author":"CK Tsao","year":"2014","unstructured":"Tsao CK, Cutting E, Martin J, Oh WK. The role of cabazitaxel in the treatment of metastatic castration-resistant prostate cancer. Ther Adv Urol. 2014;6(3):97\u2013104.","journal-title":"Ther Adv Urol"},{"key":"2958_CR3","doi-asserted-by":"crossref","unstructured":"Sathianathen NJ, Philippou YA, Kuntz GM, Konety BR, Gupta S, Lamb AD, et al. Taxane-based chemohormonal therapy for metastatic hormone-sensitive prostate cancer. Cochrane Database Syst Rev. 2018;10(10):Cd012816.","DOI":"10.1002\/14651858.CD012816.pub2"},{"key":"2958_CR4","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.ijsu.2018.06.010","volume":"56","author":"P Song","year":"2018","unstructured":"Song P, Huang C, Wang Y. The efficacy and safety comparison of docetaxel, cabazitaxel, estramustine, and mitoxantrone for castration-resistant prostate cancer: a network meta-analysis. Int J Surg. 2018;56:133\u201340.","journal-title":"Int J Surg"},{"key":"2958_CR5","doi-asserted-by":"publisher","first-page":"1851","DOI":"10.2147\/DDDT.S64940","volume":"8","author":"P Vrignaud","year":"2014","unstructured":"Vrignaud P, Semiond D, Benning V, Beys E, Bouchard H, Gupta S. Preclinical profile of cabazitaxel. Drug Des Dev Ther. 2014;8:1851\u201367.","journal-title":"Drug Des Dev Ther"},{"issue":"9747","key":"2958_CR6","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1016\/S0140-6736(10)61389-X","volume":"376","author":"JS De Bono","year":"2010","unstructured":"De Bono JS, Oudard S, Ozguroglu M, Hansen S, MacHiels JP, Kocak I, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. The Lancet. 2010;376(9747):1147\u201354.","journal-title":"The Lancet"},{"issue":"28","key":"2958_CR7","doi-asserted-by":"publisher","first-page":"3189","DOI":"10.1200\/JCO.2016.72.1068","volume":"35","author":"S Oudard","year":"2017","unstructured":"Oudard S, Fizazi K, Sengel\u00f8v L, Daugaard G, Saad F, Hansen S, et al. Cabazitaxel versus docetaxel as first-line therapy for patients with metastatic castration-resistant prostate cancer: a randomized phase III trial-FIRSTANA. J Clin Oncol. 2017;35(28):3189\u201397.","journal-title":"J Clin Oncol"},{"issue":"28","key":"2958_CR8","doi-asserted-by":"publisher","first-page":"3198","DOI":"10.1200\/JCO.2016.72.1076","volume":"35","author":"M Eisenberger","year":"2017","unstructured":"Eisenberger M, Hardy-Bessard AC, Kim CS, G\u00e9czi L, Ford D, Mourey L, et al. Phase III study comparing a reduced dose of cabazitaxel (20 mg\/m(2)) and the currently approved dose (25 mg\/m(2)) in postdocetaxel patients with metastatic castration-resistant prostate cancer-PROSELICA. J Clin Oncol. 2017;35(28):3198\u2013206.","journal-title":"J Clin Oncol"},{"issue":"1","key":"2958_CR9","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1186\/s12885-019-5342-9","volume":"19","author":"N Terada","year":"2019","unstructured":"Terada N, Kamoto T, Tsukino H, Mukai S, Akamatsu S, Inoue T, et al. The efficacy and toxicity of cabazitaxel for treatment of docetaxel-resistant prostate cancer correlating with the initial doses in Japanese patients. BMC Cancer. 2019;19(1):156.","journal-title":"BMC Cancer"},{"issue":"12","key":"2958_CR10","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1093\/jjco\/hyz108","volume":"49","author":"K Suzuki","year":"2019","unstructured":"Suzuki K, Matsubara N, Kazama H, Seto T, Tsukube S, Matsuyama H. Safety and efficacy of cabazitaxel in 660 patients with metastatic castration-resistant prostate cancer in real-world settings: results of a Japanese post-marketing surveillance study. Jpn J Clin Oncol. 2019;49(12):1157\u201363.","journal-title":"Jpn J Clin Oncol"},{"issue":"15","key":"2958_CR11","first-page":"69","volume":"35","author":"A Bahl","year":"2017","unstructured":"Bahl A, Braybrooke J. A randomised phase 2 study of 3 weekly cabazitaxel vs weekly paclitaxel chemotherapy in the first-line treatment of HER2 negative metastatic breast cancer. J Clin Oncol. 2017;35(15):69\u201376.","journal-title":"J Clin Oncol."},{"key":"2958_CR12","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.oraloncology.2017.10.018","volume":"75","author":"A Joshi","year":"2017","unstructured":"Joshi A, Patil V, Noronha V, Dhumal S, Pande N, Chandrasekharan A, et al. Results of a phase II randomized controlled clinical trial comparing efficacy of Cabazitaxel versus Docetaxel as second line or above therapy in recurrent head and neck cancer. Oral Oncol. 2017;75:54\u201360.","journal-title":"Oral Oncol"},{"key":"2958_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ejca.2017.06.037","volume":"84","author":"S K\u00fcmmel","year":"2017","unstructured":"K\u00fcmmel S, Paepke S, Huober J, Schem C, Untch M, Blohmer JU, et al. Randomised, open-label, phase II study comparing the efficacy and the safety of cabazitaxel versus weekly paclitaxel given as neoadjuvant treatment in patients with operable triple-negative or luminal B\/HER2-negative breast cancer (GENEVIEVE). Eur J Cancer. 2017;84:1\u20138.","journal-title":"Eur J Cancer"},{"issue":"3","key":"2958_CR14","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.eururo.2021.10.016","volume":"81","author":"G Baciarello","year":"2022","unstructured":"Baciarello G, Delva R, Gravis G, Tazi Y, Beuzeboc P, Gross-Goupil M, et al. Patient preference between cabazitaxel and docetaxel for first-line chemotherapy in metastatic castration-resistant prostate cancer: the CABADOC trial. Eur Urol. 2022;81(3):234\u201340.","journal-title":"Eur Urol"},{"issue":"6","key":"2958_CR15","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1002\/bco2.177","volume":"3","author":"ND James","year":"2022","unstructured":"James ND, Ali A, Pope A, Desai A, Ford D, Stevenson R, et al. Cabazitaxel versus docetaxel for treatment of metastatic castrate refractory prostate cancer. BJUI Compass. 2022;3(6):484\u201393.","journal-title":"BJUI Compass"},{"issue":"26","key":"2958_CR16","doi-asserted-by":"publisher","first-page":"2506","DOI":"10.1056\/NEJMoa1911206","volume":"381","author":"R de Wit","year":"2019","unstructured":"de Wit R, de Bono J, Sternberg CN, Fizazi K, Tombal B, W\u00fclfing C, et al. Cabazitaxel versus abiraterone or enzalutamide in metastatic prostate cancer. N Engl J Med. 2019;381(26):2506\u201318.","journal-title":"N Engl J Med"},{"issue":"1","key":"2958_CR17","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1186\/s12885-020-07131-6","volume":"20","author":"H Matsuyama","year":"2020","unstructured":"Matsuyama H, Matsubara N, Kazama H, Seto T, Tsukube S, Suzuki K. Real-world efficacy and safety of two doses of cabazitaxel (20 or 25 mg\/m(2)) in patients with castration-resistant prostate cancer: results of a Japanese post-marketing surveillance study. BMC Cancer. 2020;20(1):649.","journal-title":"BMC Cancer"},{"key":"2958_CR18","doi-asserted-by":"publisher","first-page":"395","DOI":"10.2147\/CIA.S14570","volume":"5","author":"SK Pal","year":"2010","unstructured":"Pal SK, Twardowski P, Sartor O. Critical appraisal of cabazitaxel in the management of advanced prostate cancer. Clin Interv Aging. 2010;5:395\u2013402.","journal-title":"Clin Interv Aging"},{"issue":"1","key":"2958_CR19","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1186\/s13643-021-01626-4","volume":"10","author":"MJ Page","year":"2021","unstructured":"Page MJ, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Syst Rev. 2021;10(1):89.","journal-title":"Syst Rev"},{"key":"2958_CR20","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898","volume":"366","author":"JAC Sterne","year":"2019","unstructured":"Sterne JAC, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366:l4898.","journal-title":"BMJ"},{"issue":"8","key":"2958_CR21","doi-asserted-by":"publisher","first-page":"3465","DOI":"10.1007\/s12094-025-03851-y","volume":"27","author":"IP Silva","year":"2025","unstructured":"Silva IP, de Amorim L, Piredda GV, Mass-Lindenbaum M, de Moraes FCA, Freitas PFS, et al. Cabazitaxel versus abiraterone or enzalutamide for metastatic castration-resistant prostate cancer following docetaxel failure: a systematic review and meta-analysis. Clin Transl Oncol. 2025;27(8):3465\u201376.","journal-title":"Clin Transl Oncol."},{"issue":"4","key":"2958_CR22","doi-asserted-by":"publisher","first-page":"e205","DOI":"10.1016\/j.clgc.2015.01.010","volume":"13","author":"A Omlin","year":"2015","unstructured":"Omlin A, Sartor O, Rothermundt C, Cathomas R, De Bono JS, Shen L, et al. Analysis of side effect profile of alopecia, nail changes, peripheral neuropathy, and dysgeusia in prostate cancer patients treated with docetaxel and cabazitaxel. Clin Genitourin Cancer. 2015;13(4):e205\u20138.","journal-title":"Clin Genitourin Cancer"},{"issue":"4","key":"2958_CR23","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1111\/bju.15542","volume":"129","author":"K Kreis","year":"2022","unstructured":"Kreis K, Horenkamp-Sonntag D, Schneider U, Zeidler J, Glaeske G, Weissbach L. Safety and survival of docetaxel and cabazitaxel in metastatic castration-resistant prostate cancer. BJU Int. 2022;129(4):470\u20139.","journal-title":"BJU Int"},{"key":"2958_CR24","doi-asserted-by":"publisher","first-page":"1157306","DOI":"10.3389\/fphar.2023.1157306","volume":"14","author":"M Sousa-Pimenta","year":"2023","unstructured":"Sousa-Pimenta M, Estevinho LM, Szopa A, Basit M, Khan K, Armaghan M, et al. Chemotherapeutic properties and side-effects associated with the clinical practice of terpene alkaloids: paclitaxel, docetaxel, and cabazitaxel. Front Pharmacol. 2023;14:1157306.","journal-title":"Front Pharmacol"},{"issue":"4","key":"2958_CR25","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.urolonc.2022.06.018","volume":"41","author":"T Yanagisawa","year":"2023","unstructured":"Yanagisawa T, Kawada T, Rajwa P, Mostafaei H, Motlagh RS, Quhal F, et al. Sequencing impact and prognostic factors in metastatic castration-resistant prostate cancer patients treated with cabazitaxel: a systematic review and meta-analysis. Urol Oncol. 2023;41(4):177\u201391.","journal-title":"Urol Oncol"},{"issue":"5","key":"2958_CR26","doi-asserted-by":"publisher","first-page":"155798832412851","DOI":"10.1177\/15579883241285162","volume":"18","author":"HT Hashim","year":"2024","unstructured":"Hashim HT, Khan MA, Shah SI, Al-Ghuraibawi MA, Sulaiman FA, Nasrallah J, et al. The efficacy of cabazitaxel in treating prostate cancer: a systematic review and meta-analysis. Am J Mens Health. 2024;18(5):15579883241285162.","journal-title":"Am J Mens Health"},{"issue":"2","key":"2958_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2021.100089","volume":"6","author":"A Thiery-Vuillemin","year":"2021","unstructured":"Thiery-Vuillemin A, Fizazi K, Sartor O, Oudard S, Bury D, Thangavelu K, et al. An analysis of health-related quality of life in the phase III PROSELICA and FIRSTANA studies assessing cabazitaxel in patients with metastatic castration-resistant prostate cancer. ESMO Open. 2021;6(2):100089.","journal-title":"ESMO Open"},{"issue":"28","key":"2958_CR28","doi-asserted-by":"publisher","first-page":"3181","DOI":"10.1200\/JCO.2017.72.4138","volume":"35","author":"ES Antonarakis","year":"2017","unstructured":"Antonarakis ES, Tagawa ST, Galletti G, Worroll D, Ballman K, Vanhuyse M, et al. Randomized, noncomparative, phase II trial of early switch from docetaxel to cabazitaxel or vice versa, with integrated biomarker analysis, in men with chemotherapy-na\u00efve, metastatic, castration-resistant prostate cancer. J Clin Oncol. 2017;35(28):3181\u20138.","journal-title":"J Clin Oncol"},{"issue":"5","key":"2958_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2024.103009","volume":"9","author":"P Meyer-Wilmes","year":"2024","unstructured":"Meyer-Wilmes P, Huober J, Untch M, Blohmer JU, Janni W, Denkert C, et al. Long-term outcomes of a randomized, open-label, phase II study comparing cabazitaxel versus paclitaxel as neoadjuvant treatment in patients with triple-negative or luminal B\/HER2-negative breast cancer (GENEVIEVE). ESMO Open. 2024;9(5):103009.","journal-title":"ESMO Open"},{"key":"2958_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.oraloncology.2022.106085","volume":"134","author":"V Patil","year":"2022","unstructured":"Patil V, Kumar S, Noronha V, Menon N, Nawale KP, Alone M, et al. Long term outcomes of a randomized controlled clinical trial comparing the efficacy of Cabazitaxel versus docetaxel as second-line or above therapy in recurrent head and neck cancer. Oral Oncol. 2022;134:106085.","journal-title":"Oral Oncol"},{"issue":"12","key":"2958_CR31","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.1634\/theoncologist.2016-0296","volume":"21","author":"JP Machiels","year":"2016","unstructured":"Machiels JP, Van Maanen A, Vandenbulcke JM, Filleul B, Seront E, Henry S, et al. Randomized phase II study of cabazitaxel versus methotrexate in patients with recurrent and\/or metastatic squamous cell carcinoma of the head and neck previously treated with platinum-based therapy. Oncologist. 2016;21(12):1416-e17.","journal-title":"Oncologist"},{"issue":"31","key":"2958_CR32","doi-asserted-by":"publisher","first-page":"51830","DOI":"10.18632\/oncotarget.15901","volume":"8","author":"J Fayette","year":"2017","unstructured":"Fayette J, Guigay J, Le Tourneau C, Degardin M, Peyrade F, Neidhardt EM, et al. Cabazitaxel in recurrent\/metastatic squamous cell carcinoma of the head and neck: phase II UNICANCER trial ORL03. Oncotarget. 2017;8(31):51830\u20139.","journal-title":"Oncotarget"},{"issue":"1","key":"2958_CR33","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1158\/1535-7163.MCT-14-0155","volume":"14","author":"GE Duran","year":"2015","unstructured":"Duran GE, Wang YC, Francisco EB, Rose JC, Martinez FJ, Coller J, et al. Mechanisms of resistance to cabazitaxel. Mol Cancer Ther. 2015;14(1):193\u2013201.","journal-title":"Mol Cancer Ther"},{"issue":"6","key":"2958_CR34","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1007\/s00280-018-3572-1","volume":"81","author":"GE Duran","year":"2018","unstructured":"Duran GE, Derdau V, Weitz D, Philippe N, Blankenstein J, Atzrodt J, et al. Cabazitaxel is more active than first-generation taxanes in ABCB1(+) cell lines due to its reduced affinity for P-glycoprotein. Cancer Chemother Pharmacol. 2018;81(6):1095\u2013103.","journal-title":"Cancer Chemother Pharmacol"},{"key":"2958_CR35","doi-asserted-by":"crossref","unstructured":"Maloney SM, Hoover CA, Morejon-Lasso LV, Prosperi JR. Mechanisms of taxane resistance. Cancers (Basel). 2020;12(11):3323.","DOI":"10.3390\/cancers12113323"},{"key":"2958_CR36","doi-asserted-by":"crossref","unstructured":"Xu L, Schaefer KG, King GM, Xie ZR, Bartlett MG. Insights into interactions between taxanes and P-glycoprotein using biophysical and in silico methods. J Pharm Sci. 2025;114:103708.","DOI":"10.1016\/j.xphs.2025.103708"},{"issue":"3","key":"2958_CR37","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1038\/s41416-020-0909-4","volume":"123","author":"A Koutras","year":"2020","unstructured":"Koutras A, Zagouri F, Koliou GA, Psoma E, Chryssogonidis I, Lazaridis G, et al. Phase 2 study of cabazitaxel as second-line treatment in patients with HER2-negative metastatic breast cancer previously treated with taxanes-a Hellenic Cooperative Oncology Group (HeCOG) Trial. Br J Cancer. 2020;123(3):355\u201361.","journal-title":"Br J Cancer"},{"issue":"12","key":"2958_CR38","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1038\/s41416-019-0611-6","volume":"121","author":"M Rouyer","year":"2019","unstructured":"Rouyer M, Oudard S, Joly F, Fizazi K, Tubach F, Jove J, et al. Overall and progression-free survival with cabazitaxel in metastatic castration-resistant prostate cancer in routine clinical practice: the FUJI cohort. Br J Cancer. 2019;121(12):1001\u20138.","journal-title":"Br J Cancer"},{"issue":"8","key":"2958_CR39","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1093\/jjco\/hyz051","volume":"49","author":"T Kosaka","year":"2019","unstructured":"Kosaka T, Uemura H, Sumitomo M, Harada K, Sugimoto M, Hayashi N, et al. Impact of pegfilgrastim as primary prophylaxis for metastatic castration-resistant prostate cancer patients undergoing cabazitaxel treatment: an open-label study in Japan. Jpn J Clin Oncol. 2019;49(8):766\u201371.","journal-title":"Jpn J Clin Oncol"}],"container-title":["Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13643-025-02958-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13643-025-02958-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13643-025-02958-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T08:22:19Z","timestamp":1761898939000},"score":1,"resource":{"primary":{"URL":"https:\/\/systematicreviewsjournal.biomedcentral.com\/articles\/10.1186\/s13643-025-02958-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,31]]},"references-count":39,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2958"],"URL":"https:\/\/doi.org\/10.1186\/s13643-025-02958-1","relation":{},"ISSN":["2046-4053"],"issn-type":[{"value":"2046-4053","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,31]]},"assertion":[{"value":"18 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This systematic review and meta-analysis included only studies with registered trial protocols and explicit ethics approval, ensuring compliance with ethical standards. As a secondary analysis of published data, no additional ethics approval or participant consent was required for this review.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors have given consent for publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"There is no competing interest to declare.All authors declare that they have\u00a0no financial or personal relationships\u00a0with other people or organizations that could inappropriately influence or bias their work.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"210"}}